NCT02823457View on ClinicalTrials.gov

VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

January 30, 2020

Study Completion Date

January 30, 2020

Conditions
Patient Adherence, Chronic Hepatitis C, Alcohol-related Disorders
Interventions
BEHAVIORAL

VBMI

12 week values based motivational interviewing intervention with a licensed psychologist

Trial Locations (1)

39216

GV Sonny Montgomery VAMC, Jackson

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

G.V. (Sonny) Montgomery VA Medical Center

FED

NCT02823457 - VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C | Biotech Hunter | Biotech Hunter